

WHAT IS CLAIMED IS:

1. A multi-compartment capsule comprising a therapeutically effective amount of a HMG CoA Reductase inhibitor and a therapeutically effective amount of a serotonin reuptake inhibitor in a single dosage form.
2. A multi-compartment capsule as defined in claim 1, wherein said effective amount of said HMG CoA Reductase inhibitor is between about 20 mg and 100 mg.
3. A multi-compartment capsule as defined in claim 1, wherein said HMG CoA Reductase inhibitor comprises atorvastatin.
4. A multi-compartment capsule as defined in claim 1, wherein said effective amount of said serotonin reuptake inhibitor is between about 10 mg and 300 mg.
5. A multi-compartment capsule as defined in claim 1, wherein said serotonin reuptake inhibitor comprises sertraline.
6. A method for treating hyperlipidemia and depression by administering a therapeutically effective amount of a HMG CoA Reductase inhibitor and a therapeutically effective amount of a serotonin reuptake inhibitor in a single dosage form.

7. A method for treating hyperlipidemia as defined in claim 6, wherein said effective amount of said HMG CoA Reductase inhibitor is between about 20 mg and 100 mg.

8. A method for treating hyperlipidemia as defined in claim 6, wherein said HMG CoA Reductase inhibitor comprises atorvastatin.

9. A method for treating depression as defined in claim 6, wherein said effective amount of said serotonin reuptake inhibitor is between about 50 mg and 300 mg.

10. A method for treating depression as defined in claim 6, wherein said serotonin reuptake inhibitor comprises sertraline.

11. A multi-compartment capsule comprising a therapeutically effective amount of a thiazolidinedione derivative and a therapeutically effective amount of a serotonin reuptake inhibitor in a single dosage form.

12. A multi-compartment capsule as defined in claim 11, wherein said effective amount of said thiazolidinedione derivative is between about 4 mg and 45 mg.

13. A multi-compartment capsule as defined in claim 11, wherein said thiazolidinedione derivative comprises rosiglitazone.

14. A multi-compartment capsule as defined in claim 11, wherein said effective amount of said serotonin reuptake inhibitor is between about 50 mg and 300 mg.

15. A multi-compartment capsule as defined in claim 11, wherein said serotonin reuptake inhibitor comprises paroxetine.

16. A process for treating diabetes and depression by administering a therapeutically effective amount of a thiazolidinedione derivative and a therapeutically effective amount of a serotonin reuptake inhibitor in a single dosage form.

17. A process for treating diabetes as defined in claim 16, wherein said effective amount of said thiazolidinedione derivative is between about 4 mg and 45 mg.

18. A process for treating diabetes as defined in claim 16, wherein said thiazolidinedione derivative comprises rosiglitazone.

19. A process for treating depression as defined in claim 16, wherein said effective amount of said serotonin reuptake inhibitor is between about 50 mg and 300 mg.

20. A process for treating depression as defined in claim 16, wherein said serotonin reuptake inhibitor comprises paroxetine.
21. A multi-compartment capsule comprising a therapeutically effective amount of a bisphosphonate and a therapeutically effective amount of a HMG CoA Reductase inhibitor in a single dosage form.
22. A multi-compartment capsule as defined in claim 21, wherein said effective amount of said bisphosphonate is between about 5 mg and 70 mg.
23. A multi-compartment capsule as defined in claim 21, wherein said bisphosphonate comprises alendronate.
24. A multi-compartment capsule as defined in claim 21, wherein said effective amount of HMG CoA Reductase inhibitor is between about 5 mg and 100 mg.
25. A multi-compartment capsule as defined in claim 21, wherein said HMG CoA Reductase inhibitor comprises simvastatin.
26. A process for treating osteoporosis and hyperlipidemia by administering a therapeutically effective amount of a bisphosphonate with a therapeutically effective amount of a HMG CoA Reductase inhibitor in a single dosage form.

27. A process for treating osteoporosis as defined in claim 26, wherein said effective amount of bisphosphonate is between about 5 mg and 70 mg.

28. A process for treating osteoporosis as defined in claim 26, wherein said bisphosphonate comprises alendronate.

29. A process for treating hyperlipidemia as defined in claim 26, wherein said effective amount of HMG CoA Reductase inhibitor is between about 5 mg and 100 mg.

30. A process for treating hyperlipidemia as defined in claim 26, wherein said HMG CoA Reductase inhibitor comprises simvastatin.

31. A multi-compartment capsule comprising a therapeutically effective amount of a beta-adrenergic receptor antagonist and a therapeutically effective amount of a proton pump inhibitor in a single dosage form.

32. A multi-compartment capsule as defined in claim 31, wherein said effective amount of said beta-adrenergic receptor antagonist is between about 25 mg and 300 mg.

33. A multi-compartment capsule as defined in claim 31, wherein said beta-adrenergic receptor antagonist comprises metoprolol.

34. A multi-compartment capsule as defined in claim 31, wherein said effective amount of said proton pump inhibitor is between about 20 mg and 160 mg.

35. A multi-compartment capsule as defined in claim 31, wherein said proton pump inhibitor comprises omeprazole.

36. A process for treating hypertension and gastroesophageal reflux by administering a therapeutically effective amount of a beta-adrenergic receptor antagonist and a therapeutically effective amount of a proton pump inhibitor in a single dosage form.

37. A process for treating hypertension as defined in claim 36, wherein said effective amount of said beta-adrenergic receptor antagonist is between about 25 mg and 300 mg.

38. A process for treating hypertension as defined in claim 36 wherein said beta-adrenergic receptor antagonist comprises metoprolol.

39. A process for treating gastroesophageal reflux as defined in claim 36, wherein said effective amount of said proton pump inhibitor is between about 20 mg and 160 mg.

40. A process for treating gastroesophageal reflux as defined in claim 36, wherein said proton pump inhibitor comprises omeprazole.

41. A multi-compartment capsule comprising a therapeutically effective amount of an acetylcholinesterase inhibitor and a therapeutically effective amount of an angiotensin II receptor antagonist in a single dosage form.

42. A multi-compartment capsule as defined in claim 41, wherein said effective amount of said acetylcholinesterase inhibitor is between about 5 mg and 50 mg.

43. A multi-compartment capsule as defined in claim 41, wherein said acetylcholinesterase inhibitor comprises rivastigmine.

44. A multi-compartment capsule as defined in claim 41, wherein said effective amount of said angiotensin II receptor antagonist is between about 20 mg and 360 mg.

45. A multi-compartment capsule as defined in claim 41, wherein said angiotensin II receptor antagonist comprises valsartan.

46. A process for treating Alzheimer's disease and hypertension by administering a therapeutically effective amount of an acetylcholinesterase inhibitor and a therapeutically effective amount of an angiotensin II receptor antagonist in a single dosage form.

47. A process for treating Alzheimer's disease as defined in claim 46, wherein said effective amount of said acetylcholinesterase inhibitor is between about 5 mg and 50 mg.

48. A process for treating Alzheimer's disease as defined in claim 46, wherein said acetylcholinesterase inhibitor comprises rivastigmine.

49. A process for treating hypertension as defined in claim 46, wherein said effective amount of said angiotensin II receptor antagonist is between about 20 mg and 360 mg.

50. A process for treating hypertension as defined in claim 46, wherein said angiotensin II receptor antagonist comprises valsartan.